Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.
patients ≥ 18 years with tissue-based diagnosis of mCRC
≥ 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (in case of RAS/BRAF wildtype), anti-PD1- therapy (in case of MSI/MMRd) . (Exception: Patients who have received mFOLFOXIRI +/- anti-VEGF or anti- EGFR- 1L therapy or patients with ineligibility to receive 5-FU, oxaliplatin or irinotecan can be included after 1st line.)
Due to the non-interventional design of this registry, there are no specific exclusion criteria
Interested sites that treat patients in this indication will be invited to participate in this registry
Other
Other
Not listed
Overall Survival
Overall survival with the respective treatment protocols ≥3L
Progression free survival
Progression-free survival (PFS) with the respective treatments protocols ≥3L
Overall response rate (ORR)
Overall response rate (ORR) with the respective ≥3L treatment protocols
Blinded Independent Central Review (BICR)
Blinded Independent Central Review (BICR) based on the virtual imaging-bank
Click on the lead sponsor to view all of their trials.
